Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.54 |
| ▸ | CDK1 | P06493 | 11/20 | 0.54 |
| ▸ | CDK2 | P24941 | 11/20 | 0.54 |
| ▸ | SYK | P43405 | 2/20 | 0.52 |
| ▸ | IGF1R | P08069 | 5/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.44 |
| ▸ | LCK | P06239 | 2/20 | 0.44 |
| ▸ | FYN | P06241 | 2/20 | 0.44 |
| ▸ | CSF1R | P07333 | 2/20 | 0.44 |
| ▸ | RET | P07949 | 2/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.44 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.44 |
| ▸ | MST1R | Q04912 | 2/20 | 0.44 |
| ▸ | BTK | Q06187 | 2/20 | 0.44 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13463130 | 0.87 | KDR (0.59) | KDRCDK1CDK2SYKIGF1R | |
| SCHEMBL2938897 | 0.85 | CDK1 (0.65) | KDRCDK1CDK2IGF1RCCNB1 | |
| Hydrochloric Acid SCHEMBL3581945 | 0.84 | CDK1 (0.63) | KDRCDK1CDK2IGF1RCCNB1 | |
| SCHEMBL2938043 | 0.81 | SYK (0.51) | CDK1CDK2SYKIGF1RPTK2 | |
| SCHEMBL13648484 | 0.81 | CDK1 (0.71) | KDRCDK1CDK2SYKIGF1R | |
| SCHEMBL13655130 | 0.79 | CDK1 (0.59) | KDRCDK1CDK2SYKIGF1R | |
| SCHEMBL14163347 | 0.75 | CDK1 (0.54) | KDRCDK1CDK2SYKCCNB1 | |
| SCHEMBL14112831 | 0.75 | CDK1 (0.54) | KDRCDK1CDK2SYKCCNB1 | |
| SCHEMBL4738138 | 0.75 | KDR (0.66) | KDRCDK1CDK2SYKIGF1R | |
| SCHEMBL4738131 | 0.75 | KDR (0.66) | KDRCDK1CDK2SYKIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943629-B2 | Anticancer/antitumor agents; S-(4-([4-([(1R,2R)-2-Hydroxy-1-methylpropyl]amino)-5-(trifluoromethyl)-pyrimidin-2-yl]amino)phenyl)-S-methyl-N-[(trifluoromethyl)sulphonyl]-sulphimide for example | BAYER SCHERING PHARMA AG (DE) | 2011-05-17 | — | — | US | disclosed |
| US-7943629-B2 | Anticancer/antitumor agents; S-(4-([4-([(1R,2R)-2-Hydroxy-1-methylpropyl]amino)-5-(trifluoromethyl)-pyrimidin-2-yl]amino)phenyl)-S-methyl-N-[(trifluoromethyl)sulphonyl]-sulphimide for example | BAYER SCHERING PHARMA AG (DE) | 2011-05-17 | — | — | US | disclosed |
| EP-2029552-B1 | SULFIMIDES AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AG (DE) | 2010-09-22 | — | — | EP | disclosed |
| EP-2029552-A1 | SULFIMIDES AS PROTEIN KINASE INHIBITORS | Bayer Schering Pharma AG (DE) | 2009-03-04 | — | — | EP | disclosed |
| US-20080058358-A1 | SULPHIMIDES AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058358-A1 | SULPHIMIDES AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058358-A1 | SULPHIMIDES AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| WO-2007140957-A1 | SULFIMIDES AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007140957-A1 | SULFIMIDES AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058358-A1 | SULPHIMIDES AS PROTEIN KINASE INHIBITORS | PRKCE, BRAF, PACSIN2 | KDR 1439/4885CDK1 160/4885CDK2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.